Press Releases

Biothera Pharmaceutical Inc. Appoints Barry Labinger as Chief Executive Officer

EAGAN, MN — December 9, 2015 — Biothera Pharmaceutical Inc. announced today the appointment of Barry Labinger as Chief Executive Officer, effective December 14. Biothera Pharmaceutical is developing a novel cancer immunotherapy that triggers a robust, coordinated immune response against a wide range of cancers. Mr. Labinger has nearly three decades of pharmaceutical and biotech industry experience, with leading roles at Emergent BioSolutions, Human Genome...

Read More


Biothera’s Imprime PGG and Monoclonal Antibody Therapy Alleviates Immune Suppression in Tumor Microenvironment and Increases Cancer Cell Killing

Company to Present New Preclinical Data at Society for Immunotherapy of Cancer Annual Meeting NATIONAL HARBOR, MD — November 6, 2015 — New research provides additional scientific evidence that Biothera’s mid clinical stage cancer immunotherapy Imprime PGG acts as an immune ignition switch that enables the body to recognize and kill tumor cells. The company will present the data today at the Society for Immunotherapy...

Read More


Biothera’s Imprime PGG and Anti-Angiogenic Antibodies Work in Concert to Re-orient the Immune Microenvironment to Support Cancer Killing, Study Finds

BOSTON, November 6, 2015 — New preclinical research demonstrating the combination of Biothera’s Imprime PGG and anti-angiogenic antibodies re-orients the immune microenvironment to suppress tumor growth will be presented today at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. Imprime PGG is an immune potentiator that represents the next step in immune oncology. This mid clinical stage cancer immunotherapeutic is a first-in-class, well-tolerated,...

Read More


Biothera to Present Three Abstracts at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

EAGAN, MN — November 2, 2015 — Biothera, a clinical stage biotechnology company pioneering the development of immune potentiators known as PAMPs for cancer immunotherapy, will present three abstracts at the 2015 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. The conference will take place November 5–9 at the Hynes Convention Center in Boston. PAMPs (Pathogen Associated Molecular Patterns) serve as critical recognition signals...

Read More


Kerry Acquires Wellmune® from Biothera Inc.

Tralee, Ireland and Eagan, Minnesota, U.S.A. ─ October 21, 2015 ─ Kerry Group plc, the global taste and nutrition company, has acquired Wellmune® from Biothera Inc., a natural food, beverage and supplement ingredient that is clinically proven to help strengthen the immune system. “At Kerry, cutting-edge science and technology informs everything we help shape and create. The addition of Wellmune to our portfolio offers Kerry...

Read More


Biothera Appoints Dr. Jose Iglesias as Chief Medical Officer

EAGAN, MN — October 15, 2015 — Biothera Pharmaceuticals, Inc., today announced the appointment of Jose Iglesias, M.D., as Chief Medical Officer. Dr. Iglesias will be responsible for clinical development, medical affairs, and other functions related to the advancement of Imprime PGG, the company’s cancer immunotherapy currently in multiple mid- and late-stage clinical testing. Imprime PGG is a novel, proprietary compound known as a pathogen-associated...

Read More


Biothera’s Cancer Immunotherapy Drug Imprime PGG Elicits Increased Natural Killer Cell Activation and Cancer Cell Killing

Study Further Demonstrates Imprime’s Effect in Enlisting the Innate Immune System to Eradicate Cancer NEW YORK – Sept. 18, 2015 – Imprime PGG, Biothera’s late-stage investigational cancer immunotherapy drug, enhances the tumor killing function of the innate immune system’s Natural Killer (NK) cells, according to research presented today at Inaugural International Cancer Immunotherapy Conference jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the...

Read More


Biothera’s Imprime PGG Cancer Immunotherapy Drug Activates Dendritic Cells, Leading to Enhanced T Cell Expansion and Cytokine Production

Imprime PGG, as a PAMP, effectively activates antigen presentation and drives T cell engagement NEW YORK – Sept. 18, 2015 – New data reported today at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, demonstrate that Biothera’s investigational cancer immunotherapy drug Imprime PGG enhances...

Read More


Imprime PGG Specifically Enhances the Potent Tumor Killing Activity of Neutrophils

Imprime PGG treatment enables neutrophils to kill cancer cells decorated with therapeutic monoclonal antibody NEW YORK – Sept. 16, 2015 – Research presented today by Biothera shows for the first time that cancer cells coated with therapeutic monoclonal antibodies are specifically recognized and killed by Imprime PGG-treated neutrophils. The findings were reported at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the...

Read More


Biothera’s Imprime PGG Enhances Anti-Tumor Activity of the Innate Immune System’s Macrophages

Research examines Imprime PGG’s effect on macrophages in engulfing human cancer cells NEW YORK – Sept. 16, 2015 – Research presented today at the Inaugural International Cancer Immunotherapy Conference, jointly sponsored by the Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research, demonstrates that Biothera’s cancer immunotherapy drug, Imprime PGG, enhances the anti-tumor activity of...

Read More



Page 3 of 612345...Last »